BN83495 in Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

February 28, 2011

Conditions
Prostate Cancer
Interventions
DRUG

BN83495 (Cohort 1)

20 mg daily BN83495 for 28 days

DRUG

BN83495 (Cohort 2)

40 mg daily BN83495 for 28 days

DRUG

BN83495 (Cohort 3)

60 mg daily BN83495 for 28 days

Trial Locations (3)

21231

Johns Hopkins University Medical Center, Baltimore

27705

Duke University Medical Center United States, Durham

53705

University of Wisconsin Hospital and Clinics, Madison

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY